Company
Biocon
Biocon has 21 drugs tracked on RxWires: 1 approved, 6 in Phase 3, 1 in Phase 2/3, 2 in Phase 2, 11 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| PALBOCICLIB | Approved | |
| Stelara | Phase 3 | Moderate to Severe Chronic Plaque Psoriasis |
| EQ001 | Phase 3 | Coronavirus |
| Bmab 1000 | Phase 3 | Postmenopausal Women With Osteoporosis |
| Itolizumab | Phase 3 | Graft Versus Host Disease |
| PERT-IJS plus trastuzumab, carboplatin and docetaxel | Phase 3 | HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients |
| Humira 40 MG in Prefilled Syringe | Phase 3 | Moderate Chronic Plaque Psoriasis |
| Insulin Tregopil | Phase 2/3 | Type2 Diabetes Mellitus |
| Tucatinib 150 MG | Phase 2 | HER2-positive Breast Cancer |
| Itolizumab IV infusion | Phase 2 | Acute Respiratory Distress Syndrome |
| Bmab3000 | Phase 1 | Healthy Male Participants |
| Bmab1700 | Phase 1 | Melanoma |
| Humulin ®70/30 | Phase 1 | Healthy Volunteer |
| Biocon's Human Insulin R U-500 | Phase 1 | Healthy Volunteers |
| Biocon Insulin N | Phase 1 | Healthy Volunteer |
| Tregopil | Phase 1 | Type 1 Diabetes Mellitus (T1DM) |
| IN-105 (Insulin Tregopil) | Phase 1 | Type 2 Diabetes Mellitus |
| Itolizumab [Bmab 600] | Phase 1 | Lupus Erythematosus |
| Biocon Insulin R | Phase 1 | Healthy Volunteer |
| Bmab 1200 (Biosimilar Ustekinumab) | Phase 1 | Moderate to Severe Chronic Plaque Psoriasis |
| Bmab1800 | Phase 1 | Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) |
Latest
No recent events.
Follow Biocon on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.